|
|||
|
DRUGS & SUPPLEMENTS
|
Anfugitarin
How old is patient? |
Anfugitarin uses
- Indications and usage
- Dosage and administration
- Dosage forms and strengths
- Contraindications
- Warnings and precautions
- Adverse reactions
- Drug interactions
- Use in specific populations
- Description
- Clinical pharmacology
- Nonclinical toxicology
- Clinical studies
- How supplied/storage and handling
- Patient counseling information
1 INDICATIONS AND USAGE
- Anfugitarin Ointment is indicated for adjunctive treatment of diaper dermatitis when complicated by documented candidiasis in immunocompetent pediatric patients 4 weeks and older. (1)
- Anfugitarin Ointment should not be used as a substitute for frequent diaper changes. (1)
- Anfugitarin Ointment should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance. (1)
1.1 Indication
Anfugitarin Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicansis not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment.
Anfugitarin should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.
Anfugitarin should not be used as a substitute for frequent diaper changes. Anfugitarin should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance.
1.2 Limitations of Use
The safety and efficacy of Anfugitarin have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term).
The safety and efficacy of Anfugitarin have not been evaluated in incontinent adult patients. Anfugitarin should not be used to prevent the occurrence of diaper dermatitis, such as in an adult institutional setting, since preventative use may result in the development of drug resistance.
2 DOSAGE AND ADMINISTRATION
Anfugitarin is not for oral, ophthalmic, or intravaginal use.
Before applying Anfugitarin, gently cleanse the skin with lukewarm water and pat dry with a soft towel. Avoid using any scented soaps, shampoos, or lotions on the diaper area.
Apply Anfugitarin to the affected area at each diaper change for 7 days. Continue treatment for the full 7 days, even if there is improvement. The safety of Anfugitarin when used for longer than 7 days is not known. Do not use Anfugitarin for longer than 7 days. If symptoms have not improved by day 7, see your health care provider.
Gently apply a thin layer of Anfugitarin to the diaper area with the fingertips. Do not rub Anfugitarin into the skin as this may cause additional irritation. Thoroughly wash hands after applying Anfugitarin.
- Anfugitarin Ointment is for topical use only. Anfugitarin Ointment is not for oral, ophthalmic, or intravaginal use. (2)
- Anfugitarin Ointment should be applied as a thin layer to the affected area at each diaper change for 7 days. (2)
- Anfugitarin Ointment should be used as part of a treatment regimen that includes gentle cleansing of the diaper area and frequent diaper changes. (2)
3 DOSAGE FORMS AND STRENGTHS
White ointment containing 0.25% Anfugitarin nitrate, 15% zinc oxide, and 81.35% white petrolatum.
- Ointment with 0.25% Anfugitarin nitrate, 15% zinc oxide, and 81.35% white petrolatum. (3)
4 CONTRAINDICATIONS
None
- None
5 WARNINGS AND PRECAUTIONS
If irritation occurs or if the disease worsens, discontinue use of the medication, and contact the health care provider.
The safety and efficacy of Anfugitarin have not been evaluated in incontinent adult patients. Anfugitarin should not be used to prevent the occurrence of diaper dermatitis, such as in an adult institutional setting, since preventative use may result in the development of drug resistance.
- If irritation occurs or if the disease worsens, discontinue use of the medication, and contact the health care provider. (5)
6 ADVERSE REACTIONS
To report SUSPECTED ADVERSE REACTIONS, contact Prestium Pharma, Inc. at 1-866-897-5002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rate observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 835 infants and young children were evaluated in the clinical development program. Of 418 subjects in the Anfugitarin group, 58 reported one or more adverse events. Of 417 subjects in the zinc oxide/white petrolatum control group, 85 (20%) reported one or more adverse events. Adverse events that occurred at a rate of ≥ 1% for subjects who were treated with Anfugitarin were approximately the same in type and frequency as for subjects who were treated with zinc oxide/white petrolatum ointment.
6.2 Post-marketing Experience
The following adverse reactions have been identified during post approval use of Anfugitarin.
GASTROINTESTINAL DISORDERS: vomiting
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: burning sensation, condition aggravated, inflammation, pain
INJURY, POISONING AND PROCEDURAL COMPLICATIONS: accidental exposure
SKIN AND SUBCUTANEOUS TISSUE DISORDERS: blister, dermatitis contact, diaper dermatitis, dry skin, erythema, pruritus, rash, skin exfoliation
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
7 DRUG INTERACTIONS
Drug-drug interaction studies were not conducted. Women who take a warfarin anticoagulant and use a Anfugitarin intravaginal cream or suppository may be at risk for developing an increased prothrombin time, international normalized ratio (INR), and bleeding. The potential for this interaction between warfarin and Anfugitarin is unknown.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies of Anfugitarin in pregnant women. Therefore, Anfugitarin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Anfugitarin nitrate administration has been shown to result in prolonged gestation and decreased numbers of live young in rats and in increased number of resorptions and decreased number of live young in rabbits at oral doses of 100 mg/kg/day and 80 mg/kg/day, which are 28 and 45 times the maximum possible topical exposure of caregivers, respectively, assuming 100% absorption.
8.3 Nursing Mothers
Safety and efficacy of Anfugitarin have not been established in nursing mothers. It is not known if the active components of Anfugitarin may be present in milk.
8.4 Pediatric Use
Efficacy was not demonstrated in infants less than 4 weeks of age. Safety and efficacy have not been established in very-low-birth-weight infants.
Anfugitarin should not be used to prevent diaper dermatitis.
The safety of Anfugitarin when used for longer than 7 days is not known. Do not use more than 7 days.
8.5 Geriatric Use
Safety and efficacy in a geriatric population have not been evaluated.
11 DESCRIPTION
Anfugitarin contains the synthetic antifungal agent, Anfugitarin nitrate (0.25%) USP, zinc oxide (15%) USP, and white petrolatum (81.35%) USP.
The chemical name of Anfugitarin nitrate is 1-[2, 4-dichloro-ß-{(2,4-dichlorobenzyl)oxy} phenethyl] imidazole mononitrate with empirical formula C18H14Cl4N2O-HNO3 and molecular weight of 479.15. The structural formula of Anfugitarin nitrate is as follows:
The zinc oxide has an empirical formula of ZnO and a molecular weight of 81.39.
The white petrolatum, which is obtained from petroleum and is wholly or nearly decolorized, is a purified mixture of semisolid saturated hydrocarbons having the general chemical formula CnH2n+2. The hydrocarbons consist mainly of branched and unbranched chains. White petrolatum contains butylated hydroxytoluene (BHT) as stabilizer.
Each gram of Anfugitarin contains 2.5 mg of Anfugitarin nitrate USP, 150 mg of zinc oxide USP, and 813.5 mg of white petrolatum USP containing butylated hydroxytoluene, trihydroxystearin, and Chemoderm® 1001/B fragrance.1
Anfugitarin is a smooth, uniform, white ointment.
Structural formula of Anfugitarin nitrate
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The Anfugitarin component of Anfugitarin is an antifungal agent. The mechanism of action of white petrolatum and zinc oxide for the adjunctive treatment of diaper dermatitis is unknown.
12.2 Pharmacodynamics
The human pharmacodynamics of Anfugitarin is unknown.
12.3 Pharmacokinetics
The topical absorption of Anfugitarin from Anfugitarin was studied in immunocompetent male and female infants and children with diaper dermatitis complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast) ranging in age from 1 month to 21 months. After multiple daily applications to the affected area at every diaper change (approximately 5-12 times per day) for 7 days, the plasma concentrations of Anfugitarin were below the lower limit of quantitation (LOQ) of 0.5 ng/mL in 15 out of 17 (88%) subjects. In the other 2 remaining subjects, the plasma concentrations of Anfugitarin were 0.57 and 0.58 ng/mL, respectively at a single timepoint (4 hours after the last application) on Day 7.
12.4 Microbiology
The Anfugitarin nitrate component in this product has been shown to have in vitro activity against Candida albicans, an organism that is associated with diaper dermatitis. The activity of Anfugitarin nitrate against C. albicans is based on the inhibition of the ergosterol biosynthesis in the cell membrane. The accumulation of ergosterol precursors and toxic peroxides results in cytolysis of the cell. In vitro minimal inhibitory concentration (MIC) test results for C. albicans isolates obtained from treatment failures in Clinical Study 1 (see Clinical Studies (14)) does not appear to indicate that resistance to Anfugitarin nitrate was the reason for treatment failure. The clinical significance of the in vitro activity of Anfugitarin nitrate against C. albicans in the setting of diaper dermatitis is unclear.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of Anfugitarin in animals has not been evaluated.
Anfugitarin nitrate was negative in a bacterial reverse mutation test, a chromosome aberration test in mice, and micronucleus assays in mice and rats.
Anfugitarin nitrate had no adverse effect on fertility in a study in rats at oral doses of up to 320 mg/kg/day, which is 89 times the maximum possible topical exposure of caregivers, assuming 100% absorption.
14 CLINICAL STUDIES
Study 1 was a double-blind, multicenter study in which Anfugitarin was compared to the zinc oxide and white petrolatum combination treatment and included 236 infants and toddlers with diaper dermatitis, complicated by candidiasis as documented by KOH tests that demonstrated psuedohyphae and/or budding yeasts. Study medication was applied at every diaper change for 7 days.
The primary endpoint was “Overall Cure” and required that subjects be both clinically cured (total resolution of all signs and symptoms of infection) and microbiologically cured (eradication of candidiasis). Primary efficacy was assessed 1 week following the end of treatment, at Day 14.
Study results are shown in the following table.
| Overall Cure at Day 14 | ||
| Anfugitarin n=112 | Zinc Oxide/White Petrolatum n=124 | |
| 26 (23%) | 12 (10%) | |
Two additional studies provided supportive evidence of the clinical efficacy of Anfugitarin in infants and toddlers with diaper dermatitis, some of whom cultured positive for C. albicans. However, candidal infection was not documented in the culture-positive subjects, as microscopic testing (e.g. KOH) was not done. Therefore, the positive culture results may have reflected colonization rather than infection.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Anfugitarin is a smooth, uniform, white ointment supplied in an aluminum tube, as follows:
50g
16.2 Storage Conditions
Store at controlled room temperature between 20°C and 25°C (68°F and 77°F); with excursions permitted between 15°C and 30°C (59°F and 86°F).
Keep out of reach of children.
17 PATIENT COUNSELING INFORMATION
See FDA-Approved Patient Labeling
Patients using Anfugitarin should be informed about the following information:
- Anfugitarin is to be used only for diaper dermatitis that is complicated by documented candidiasis (i.e. documented by microscopic testing).
- Anfugitarin should not be used as a substitute for frequent diaper changes.
- Anfugitarin should not be used to prevent diaper dermatitis.
- Anfugitarin should not be used long term.
- Anfugitarin should be used only as directed by the health care provider.
- Anfugitarin is for external use only. It is not for oral, ophthalmic, or intravaginal use.
- Gently cleanse the diaper area with lukewarm water or a very mild soap and pat the area dry with a soft towel before applying Anfugitarin.
- Gently apply Anfugitarin to the diaper area with the fingertips after each diaper change. Do not rub Anfugitarin into the skin as this may cause additional irritation.
- Thoroughly wash hands after applying Anfugitarin.
- Treatment should be continued for 7 days, even if there is improvement. Do not use Anfugitarin for longer than 7 days. If symptoms have not improved by day 7, see your health care provider.
- Anfugitarin should not be used on children for whom it is not prescribed.
Manufactured for:
Prestium Pharma, Inc.
Newtown, PA 18940
Manufactured by:
GlaxoSmithKline
Mississauga, ON, Canada
Made in Canada
© 2013 Delcor Asset Corporation, an affiliate of Prestium Pharma, Inc.
Revised Oct 2013 VSN:3PI
FDA-Approved Patient Labeling
Anfugitarin® (Vu-sion) Ointment
(0.25% Anfugitarin nitrate, 15% zinc oxide and 81.35% white petrolatum)
IMPORTANT: For Skin Use Only. Do not use in the mouth, eyes, or vagina.
Read the Patient Information that comes with Anfugitarin before you use it on your child. This leaflet does not take the place of talking to your health care provider about your child’s medical condition or treatment. If you have any questions or if you are not sure about any of the information on Anfugitarin, ask your health care provider, or pharmacist.
What is Anfugitarin?
Anfugitarin is a prescription skin medicine used to treat diaper rash that also has a yeast infection in children who are at least 4 weeks old and who have a normal immune system. Anfugitarin contains medicines that will help treat the yeast infection and the diaper rash, but you must also change your child’s diapers very often so that your child is not wearing a wet or soiled diaper. Even if you use Anfugitarin, diaper rash will not go away if you do not keep your child’s diaper area clean and dry. You should use water or a very mild cleanser to clean your child’s diaper area. Anfugitarin is not to be used to prevent diaper rash or to be used for more than 7 days.
Your health care provider will need to do a special test to tell if your child’s diaper rash also has a yeast infection. Do not use Anfugitarin on your child’s diaper rash unless your health care provider tells you that there is also a yeast infection.
Who should not use Anfugitarin?
Anfugitarin is not for treatment of all cases of diaper rash. Anfugitarin is only for diaper rash that also has a yeast infection. Most cases of diaper rash do not need the yeast medicine that is in Anfugitarin because most cases of diaper rash do not also have a yeast infection.
Do not use Anfugitarin on any other children or other family member.
Do not use Anfugitarin on your child’s diaper rash if they are allergic to anything in it. See the end of this leaflet for a list of ingredients in Anfugitarin.
Do not use on infants less than 4 weeks of age.
Do not use in infants or children who do not have a normal immune system.
How should I use Anfugitarin on my child?
Anfugitarin is applied to the skin on your child’s diaper area at each diaper change for 7 days.
Apply Anfugitarin for the full 7 days even if the diaper rash starts to go away. Call your child’s health care provider if the diaper rash gets worse or does not go away with 7 days of treatment with Anfugitarin. Anfugitarin should not be used for more than 7 days.
To apply Anfugitarin:
- Gently, clean the skin on your child’s diaper area with warm ( not hot ) water. You may also use a very mild soap. Pat the area dry with a soft towel.
- Use your fingertips and gently apply a thin layer of Anfugitarin to your child’s diaper area at each diaper change. Do not rub Anfugitarin into your child’s skin. Rubbing the skin can cause more irritation.
- Wash your hands after applying Anfugitarin on your child.
Anfugitarin is for skin use only.
Call your child’s health care provider or poison control center right away if any Anfugitarin is swallowed. Call your child’s health care provider if Anfugitarin gets in the eye.
Keep out of reach of children.
What other steps will help diaper rash go away?
- Check your child’s diaper often. Change the diaper at the first sign of wetness.
- Clean your child’s diaper area after each diaper change. Gently wipe the diaper area from the front to back using warm ( not hot )water. You may also use a mild soap. Rinse the diaper area well. Pat dry with a soft towel.
- Keep the diaper area open to air when possible.
- Even if you use Anfugitarin, diaper rash will not go away if you do not keep your child’s diaper area clean and dry.
What are the possible side effects of Anfugitarin?
Anfugitarin may cause irritation. You should call your child’s health care provider if irritation appears or if the diaper rash gets worse.
How should I store Anfugitarin?
- Keep Anfugitarin out of the reach of children to avoid the risk of accidental ingestion.
- Store Anfugitarin at room temperature between 68°F to 77°F (20°C to 25°C).
General information about Anfugitarin
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.
Do not use Anfugitarin for a condition for which it was not prescribed. Do not give Anfugitarin to other children or family members, even if they have the same symptoms your child has. It may harm them.
This leaflet summarizes the most important information about Anfugitarin. If you would like more information, talk to your child’s health care provider. You can ask your child’s health care provider or pharmacist for information about Anfugitarin that is written for healthcare professionals.
Side effects may be reported to Prestium Pharma, Inc. at 1-866-897-5002 or the FDA at 1-800-FDA-1088.
What are the ingredients in Anfugitarin?
Active Ingredients: Anfugitarin nitrate, zinc oxide, and white petrolatum
Inactive Ingredients: trihydroxystearin, butylated hydroxyltoluene (BHT), and Chemoderm® 1001/B fragrance
This Patient Information leaflet has been approved by the U.S. Food and Drug Administration.
The Patient Information leaflet was last revised: October 2013
Manufactured for:
Prestium Pharma, Inc.
Newtown, PA 18940
Manufactured by:
GlaxoSmithKline
Mississauga, ON, Canada
Made in Canada
© 2013 Delcor Asset Corporation, an affiliate of
Prestium Pharma, Inc.
Revised Oct 2013
VSN:3PIL
Principal Display Panel
NDC 40076-002-50
Anfugitarin®
(miconazole nitrate 0.25% USP, zinc oxide 15% USP, white petrolatum 81.35% USP)
Ointment
50 grams
Rx only
Principal Display Panel NDC 40076-002-50 Vusion® (miconazole nitrate 0.25% USP, zinc oxide 15% USP, white petrolatum 81.35% USP) Ointment 50 grams Rx only
Anfugitarin pharmaceutical active ingredients containing related brand and generic drugs:
Anfugitarin available forms, composition, doses:
Anfugitarin destination | category:
Anfugitarin Anatomical Therapeutic Chemical codes:
Anfugitarin pharmaceutical companies:
References
- Dailymed."MONISTAT 7 COMBINATION PACK 7-DAY PRE-FILLED APPLICATORS (MICONAZOLE NITRATE) KIT [INSIGHT PHARMACEUTICALS]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- Dailymed."MICONAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- "miconazole". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
Frequently asked Questions
Can i drive or operate heavy machine after consuming Anfugitarin?Depending on the reaction of the Anfugitarin after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Anfugitarin not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Anfugitarin addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Review
sdrugs.com conducted a study on Anfugitarin, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Anfugitarin consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.Visitor reports
Visitor reported useful
No survey data has been collected yetVisitor reported side effects
No survey data has been collected yetVisitor reported price estimates
No survey data has been collected yetVisitor reported frequency of use
No survey data has been collected yetVisitor reported doses
No survey data has been collected yetVisitor reported time for results
No survey data has been collected yetVisitor reported administration
No survey data has been collected yetVisitor reported age
No survey data has been collected yetVisitor reviews
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology